IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS SUBSIDIARY LISTING
Phar ma ceu ti cal Sales: US$ 22-24 mil lion
Prod ucts (% of Sales by Lead ing 5): 90-95%
Ther a peu tic Classes (% of Sales by Lead ing
5): 90-95%
Dose Forms (% of Sales by Lead ing 5): n.a.
Prin ci pal Prod ucts:
XORIMAX (cephalosporin)
PIRAMIL (ACE in hib i tor plain)
OMNITROPE (hor mone growth)
SUMIGRA (antimigraine prep a ra tion)
CILON (an ti de pres sant)
Ther a peu tic Range:
antibacterials sys temic 46%
renin-an gio ten sin sys tem agents 24%
hor mones other 14%
an al ge sics 5%
psychoanaleptics 4%
Lead ing Dose Forms:
coated tab lets 56%
tab lets 28%
vi als 16%
PORTUGAL
BEXAL
Full Name: Bexal-Produtos Farmaceuticos, S.A.
Street Ad dress: Alameda da Beloura, Ed. EE1 -
2.andar, Escritorio 15, Quinta da Beloura,
P-2710-693 Sintra
Tel: +351 21 924 19 11
Fax: +351 21 924 98 04
De scrip tion: Im porter, dis trib u tor, pro moter,
sales/detailer. Prod uct ranges in clude: phar ma -
ceu ti cal products.
Con tacts (Pharm): Chair man: Raul Oliveira;
Com mer cial Op er a tions: Josue Cachulo; Gen eral
Con tact: Ana Agostinho
NOVARTIS
Full Name: Novartis Farma - Produtos
Farmaceuticos SA
Postal Ad dress: Apartado 200, P-2711-901
Sintra
Street Ad dress: Rua do Centro Empresarial, Ed.
8, Quinta da Beloura, P-2710-444 Sintra
Tel: +351 21 000 86 00
Fax: +351 21 000 86 06
De scrip tion: Re searcher, im porter, dis trib u tor,
pro moter, sales/detailer. Prod uct ranges in clude:
phar ma ceu ti cal prod ucts (branded, pre scrip tion,
non-pre scrip tion), hos pi tal pharmaceuticals, bi o -
log i cal prod ucts, bio tech nol ogy prod ucts, oph thal -
mic prod ucts, vet er i nary pharmaceuticals. Es tab -
lished 1997. Di vi sions in clude: Ciba Vi sion
(ophtalmological products); Animal Health.
Con tacts (Pharm): Chair man: Al ex an der
Triebnigg; Com mer cial Op er a tions: Jose Al bu -
quer que; Mar ket Re search: Maria E. Pinto; Re -
search & De vel op ment: Rui Marques; Gen eral
Con tact: Maria Joao Dias
Sub sid iary of: Novartis, Swit zer land (100%)
Phar ma ceu ti cal Sales: US$ 130-140 mil lion
Prod ucts (% of Sales by Lead ing 5): 60-65%
Ther a peu tic Classes (% of Sales by Lead ing
5): 70-75%
Dose Forms (% of Sales by Lead ing 5):
95-100%
Prin ci pal Prod ucts:
CO-DIOVAN (an gio ten sin-II an tag o nist com bi na -
tion)
DIOVAN (an gio ten sin-II an tag o nist plain)
VOLTAREN (antirheumatic non-steroidal)
LESCOL (cho les terol/triglyceride reg u lat ing prep -
a ra tion)
STALEVO (antiparkinson drug)
Ther a peu tic Range:
renin-an gio ten sin sys tem agents 43%
anti rheu ma tics sys temic 12%
lipid-reg u lat ing/antiatheroma prep a ra tions 7%
antiparkinson drugs 6%
immunosuppressive agents 4%
Lead ing Dose Forms:
coated tab lets 63%
tab lets 19%
cap sules 11%
liq uids 3%
med i cal dress ings 2%
NOVARTIS CON SUMER HEALTH
Street Ad dress: Avenida Jose Malhoa No. 16B,
1., 1.2, P-1099-092 Lisboa
Tel: +351 21 781 10 00
Fax: +351 21 781 10 80
Email: nch.por tu gal@ch.novartis.com
De scrip tion: Pro moter, sales/detailer. Prod uct
ranges in clude: phar ma ceu ti cal prod ucts
(branded, pre scrip tion, non-pre scrip tion), hos pi -
tal pharmaceuticals, di etetic/nu tri tional prod ucts,
oph thal mic prod ucts. Es tab lished 1997. 68 phar -
ma ceu ti cal employees in 2008.
Rep re sen ta tives/De tail ers (Pharm, Num -
ber): 32 (2008)
Con tacts (Pharm): Chair man: Maria Do Ceu
Correia; Com mer cial Op er a tions: Faustino
© 2009 IMS Health In cor po rated or its af fil i ates Page 198